Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-69.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -98.36% |
| Return on Assets (Trailing 12 Months) | -82.81% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.87 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.45 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.71 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.77 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 13.89M |
| Free Float | 13.07M |
| Market Capitalization | $471.00M |
| Average Volume (Last 20 Days) | 0.43M |
| Beta (Past 60 Months) | 3.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |